The therapeutic effect and its mechanism of cardiomyocyte-specific ADAM17 deficiency on doxorubicin-induced cardiomyopathy, and whether it interferes with the anti-tumor effects of doxorubicin have not been reported. This evidence concerns the gene ADAM17 and neoplasm.